Juvenile Offender HIV Prevention and Drug Abuse Services (Day Treatment)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01922297|
Recruitment Status : Completed
First Posted : August 14, 2013
Last Update Posted : August 25, 2015
|Condition or disease||Intervention/treatment||Phase|
|Risk Behavior Substance Abuse Delinquency||Other: Day Treatment MDFT-HIV Other: Day Treatment SAU||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||121 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Juvenile Offender HIV Prevention and Drug Abuse Services|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||April 2015|
|Actual Study Completion Date :||April 2015|
Experimental: Day Treatment MDFT-HIV
Multidimensional Family Therapy (MDFT)is an integrative treatment approach that has blended family therapy, individual therapy, drug counseling, and multiple systems oriented intervention approaches (Liddle 1999). DT-MDFT-HIV includes a state-of-the-art family-based HIV prevention component into the core MDFT intervention specifically targeting high-risk sexual behavior in clinical sample teens.
Other: Day Treatment MDFT-HIV
MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.
Other Name: DT-MDFT-HIV
Day Treatment SAU
The DT-Services as Usual (SAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions. It is an adolescent substance abuse treatment and services consistent with those recommended for juvenile justice-involved drug abusing youth (Cooper & Bartlett 1998; National Institute of Justice, 2001).
Other: Day Treatment SAU
Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall & Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
Other Name: DT-SAU
- Substance Use [ Time Frame: Changes in substance use from intake through the 24-month follow-up ]The Timeline Follow-Back Method, Personal Experiences Inventory and Urinalyses will be used to measure substance use
- HIV Associated Sexual Risk Behaviors [ Time Frame: Changes in HIV Associated Sexual Risk Behaviors from intake to the 24-month follow-up ]Timeline Followback for Sexual Risk Behavior, Urinalysis for STD testing and HIV/STD Risk Assessment Measure
- Delinquency [ Time Frame: Changes in delinquency from intake through the 24-month follow-up ]Juvenile Justice records and the Service Utilization Interview
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01922297
|United States, Florida|
|University of Miami Miller School of Medicine|
|Miami, Florida, United States, 33136|
|Principal Investigator:||Howard A Liddle, EdD||University of Miami|